Literature DB >> 19923467

Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice.

Jeong Kim1, Katharina Lahl, Shohei Hori, Christoph Loddenkemper, Ashutosh Chaudhry, Paul deRoos, Alexander Rudensky, Tim Sparwasser.   

Abstract

We have recently described two independent mouse models in which the administration of diphtheria toxin (DT) leads to specific depletion of regulatory T cells (Tregs) due to expression of DT receptor-enhanced GFP under the control of the Foxp3 promoter. Both mouse models develop severe autoimmune disorders when Foxp3(+) Tregs are depleted. Those findings were challenged in a recent study published in this journal suggesting the expression of Foxp3 in epithelial cells as the cause for disease development. By using genetic, cellular, and immunohistochemical approaches, we do not find evidence for Foxp3-expression in nonhematopoietic cells. DT injection does not lead to a loss of epithelial integrity in our Foxp3-DTR models. Instead, Foxp3 expression is Treg-specific and ablation of Foxp3(+) Tregs leads to the induction of fatal autoimmune disorders. Autoimmunity can be reversed by the adoptive transfer of Tregs into depleted hosts, and the transfer of Foxp3-deficient bone marrow into T cell-deficient irradiated recipients leads to full-blown disease development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19923467     DOI: 10.4049/jimmunol.0804308

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  73 in total

Review 1.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

2.  Efficient expansion of cryopreserved CD4(+)CD25(+)CD127(lo/-) cells in Type 1 diabetes.

Authors:  Anna Rydén; Maria Faresjö
Journal:  Results Immunol       Date:  2011-08-22

3.  Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points.

Authors:  Kirsten K Dietze; Gennadiy Zelinskyy; Kathrin Gibbert; Simone Schimmer; Sandra Francois; Lara Myers; Tim Sparwasser; Kim J Hasenkrug; Ulf Dittmer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

Review 4.  Regulatory T cells turn pathogenic.

Authors:  Jitao Guo; Xuyu Zhou
Journal:  Cell Mol Immunol       Date:  2015-03-16       Impact factor: 11.530

Review 5.  Treg Fragility: A Prerequisite for Effective Antitumor Immunity?

Authors:  Abigail E Overacre-Delgoffe; Dario A A Vignali
Journal:  Cancer Immunol Res       Date:  2018-08       Impact factor: 11.151

6.  Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells.

Authors:  Jens Loebbermann; Lydia Durant; Hannah Thornton; Cecilia Johansson; Peter J Openshaw
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 7.  Microbiota and autoimmunity.

Authors:  Alexander V Chervonsky
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-03-01       Impact factor: 10.005

8.  Tumor suppressor and T-regulatory functions of Foxp3 are mediated through separate signaling pathways.

Authors:  Emil Heinze; Grace Chan; Rachel Mory; Raz Khavari; Asif Alavi; Sue Y Chung; Robert N Nishimura; Richard H Weisbart
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

9.  CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells.

Authors:  Nora Manzke; Ilseyar Akhmetzyanova; Kim J Hasenkrug; Mirko Trilling; Gennadiy Zelinskyy; Ulf Dittmer
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 10.  Immunometabolism and autoimmunity.

Authors:  Jenny Freitag; Luciana Berod; Thomas Kamradt; Tim Sparwasser
Journal:  Immunol Cell Biol       Date:  2016-08-26       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.